A group of leading interventional cardiologists has launched an attack on the growing role of appropriate use criteria (AUC) for PCI in the U.S. They argue that severe flaws in current guidelines render unreliable attempts to assess the rate of appropriate procedures.<\/p>\n
In a paper published in <\/a>JACC: Cardiovascular Interventions<\/a>,<\/em>\u00a0Steven Marso and colleagues (Paul Teirstein, Dean Kereiakes, Jeffrey Moses, John Lasala, and J Aaron Grantham) criticize a\u00a0study in\u00a0JAMA<\/em>\u00a0published last year<\/a>\u00a0from the National Cardiovascular Data Registry (NCDR)\u00a0that found a large degree of inappropriate or uncertain PCI procedures, as well as a wide range of variability among institutions. Marso et al. write that\u00a0the\u00a0JAMA<\/em>\u00a0paper sensationalized the data by focusing attention on the low rate of appropriate indications for nonacute PCI — 50.4% — while failing to point out that the study found that 84.6% of procedures in the entire study population — acute and nonacute alike — were deemed appropriate.\u00a0Furthermore, given the imprecision built into the system, they ask: What is the “acceptable threshold” of inappropriate PCI?<\/p>\n The authors write that the AUC panel “purposefully limited involvement of the interventional community during the development process” in order to avoid having a majority of committee members “whose livelihood is tied to the technology under study.” But the\u00a0under-representation of interventionalists may have biased the results, they argue. One particular case as graded by the AUC panel was the most common reason for cases to be categorized as inappropriate: the AUC committee decided that PCI was inappropriate for\u00a0a patient with 1- to 2-vessel disease, no proximal LAD involvement or prior CABG, class I or II symptoms, low-risk noninvasive findings, and on no or minimal medications. But most clinicians believe this is an uncertain but not inappropriate indication, they say. \u00a0The AUC panel may have “got this one wrong,” they write.<\/p>\n Marso et al. also point to the “lack of specific criteria for interpreting” stress tests in the NCDR database. In addition, they disagree with the inappropriate classification of most cases of\u00a0class II angina before medical therapy has been attempted, arguing that both COURAGE and BARI 2D showed that PCI is a valid option for these patients.\u00a0Finally, the authors argue that the\u00a0NCDR database contains numerous inaccuracies, including misclassification of patients’ angina status or noninvasive risk assessment.<\/p>\n One striking feature of the controversy is that two of the authors of the\u00a0JAMA<\/em>\u00a0paper (Paul Chan and John Spertus) and two of the authors of the JACC: Cardiovascular Interventions<\/em>\u00a0paper (Steven Marso and Aaron Grantham) are all at the same institution: Saint Luke’s Mid America Heart Institute in Kansas City, Missouri.\u00a0Marso et al.\u00a0 state that 56% of cases classified as inappropriate at their institution “were misclassified\u00a0 due to incorrectly coding CCS class status, not documenting angina equivalents, or inaccurate documentation of the noninvasive risk assessment findings.”<\/p>\n Until the NCDR database is fixed, Marso et al. write, “it could be argued” that the authors “should refrain from approving AUC-related clinical studies until such time that assurances are both valid and reliably collected.”<\/p>\n